AHA GUIDELINES Bundle (free trial)

Atrial Fibrillation 2023 Update

AHA GUIDELINES Apps brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/387790

Contents of this Issue

Navigation

Page 58 of 131

59 Active bleeding associated with oral anticoagulant Non-life-threatening bleeding • Supportive measures • Consider hemodialysis (dabigatran) • Hold an anticoagulant Life-threatening bleeding or uncontrolled major bleeding due to which oral anticoagulant Dabigatran Warfarin Idarucizumab (1, B-NR) Activated PCC if idarucizumab is not available (2a, C-LD) 4-factor PCC and intravenous vitamin K (1, A)

Articles in this issue

Archives of this issue

view archives of AHA GUIDELINES Bundle (free trial) - Atrial Fibrillation 2023 Update